http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102020006049-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd6710ac6cd84faff1dc5bfa892af700 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7034 |
| filingDate | 2020-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_758fec8067b52bb047c3e3313ddb02c6 |
| publicationDate | 2022-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-102020006049-A1 |
| titleOfInvention | deoxycholic acid and its compounds for use in the treatment of diseases |
| abstract | The subject matter of the invention is the use of deoxycholic acid and its compounds for use in the treatment of diseases with corona viruses (CoV). Corona viruses trigger flu-like respiratory diseases. The SARS-CoV-2 in particular has spread into a global pandemic. To date, there is no adequate therapeutic treatment option for viremia with a coronavirus. The object of the invention is to increase the effectiveness of the non-specific immune system at the beginning of a CoV disease (about day 1-4). This should work towards an easier course of the disease. Free deoxycholic acid (C 24 H 40 O 4 , CAS: 83-44-3) is used in a pharmaceutically effective amount as the active ingredient in a formulation for the treatment of a CoV disease, or its targeted compounds. Deoxycholic acid has the ability to stimulate the non-specific immune system, including macrophages. The use of deoxycholic acid according to the invention in the first phase of a CoV disease opens up the possibility of treating the emerging viremia before the phase of pulmonary manifestation. If an effective intervention is successful here, the course of the disease is alleviated and the number of serious cases reduced. As a result, the length of time patients stay in hospital is reduced, which would have decisively positive consequences for the patient, the health systems and economies. |
| priorityDate | 2020-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.